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causes for oedema including nephropathy, cardiac failure, hepatic
cirrhosis, and hypoalbuminemia due to any other cause, were
excluded by renal and liver function tests, thyroid profile, ECG and
baseline echocardiography. Varicose veins were ruled out by
clinical examination. Amlodipine therapy was substituted in all
the cases with an efficacy e equivalent dose of Cilnidipine (5mg of
Amlodipine ¼ 10 mg of Cilnidipine). Clinical assessment of ankle
oedema and measurement of bilateral ankle circumference, body
weight, blood pressure, and pulse rate were taken at the onset of
the study and after 4 weeks of Cilnidipine therapy.
Results: Out of 56 patients included in the study, 32 (57.1%) were
male. Mean age of patients were 58 ± 9.6 yrs and average duration
of Amlodipine therapy at the time of inclusion in the study was 12
± 3.5 months. 40 (71.4%) patients were receiving the 5mg of
Amlodipine daily. At completion of the study, oedema had
resolved in all the patients. There was a significant decreases in
bilateral ankle circumference and body weight (P<0.001). There
was no significant change in mean arterial blood pressure and
pulse rate.
Conclusions: Therapy with Cilnidipine resulted in complete res-
olution of Amlodipine induced oedema in all the cases without
significant worsening of hypertension or tachycardia. Cilnidipine
is an acceptable alternative antihypertensive drug for patients
with Amlodipine induced oedema.
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Objective: Recent evidence suggests close obesity and arterial
hypertension association. Both pathological states are character-
ized by low-grade inflammation which result in adipokines
dysfunction: increased activity of proinflammatory cytokines,
such as tumor necrosis factor e a (TNF-a), interleukin-6 (IL-6) and
decreased activity of anti-inflammatory cytokines e interleukin-
10 (IL-10).
The aim of our research was study relationships between serum
TNF-a and IL-10 concentrations and external breathing function
disorders in hypertensive patients with obesity.
Methods: 55 Patients with arterial hypertension (AH) were
examined. Serum TNF-a and IL-10 levels by ELISA were detected.
All patients underwent anthropometry and spirography. Patients
were divided into 3 group depend on body mass and FEV1 means:
1 gr. e hypertensives with normal body mass; 2nd gr. e obesity-
related hypertensives without bronchial obstruction (FEV1 >80%);
3rd gr. e obesity-related hypertensives with bronchial obstruction
(FEV1 <80%).
Results: Serum TNF-a (1st gr. e 3.32 ± 1.3 pg/ml, 2nd gr. 6.37 ± 0.6
pg/ml, 3rd gr. e 13.78 ± 4.1 pg/ml; p < 0.05 in all cases) levels
increasing were found in relation to obesity and bronchial
obstruction development. IL-10 serum levels decreased depend on
obesity progression to attainminimummeans in AH patients with
obesity and bronchial obstruction syndrome (1st gr. e 9.25 ± 1.8
pg/ml, 2nd gr. e 6.57 ± 0.5 pg/ml, 3rd gr. e 4.05 ± 0.9 pg/ml; p < 0.05
in all cases).
Conclusion: Obtained data demonstrate TNF-a levels elevation
and IL-10 levels reduction with maximum changes in obesity-
associated arterial hypertension with obstructive disorders of
external breathing function. Our results suggest possibility of
TNF-a and IL-10 involving to obstructive type of ventilation dis-
orders development in the patients with AH and obesity.
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Background: The potential use of assays of BNP for detection of
diastolic abnormalities associated with alterations in blood pres-
sure has not been elucidated.
Objective: This study was designed to determine whether
increased plasma concentrations of BNP sensitively reflect
abnormal diastolic function associated with hypertension.
Methods: We studied 60 patients with a primary diagnosis of
Hypertention. All patients were studied with the use of pulsed
Doppler transmitral flow velocity and color Tissue Doppler echo-
cardiography for the evaluation of left ventricular diastolic func-
tion. Serum BNP was determined with a sandwich immunoassay
on ‘Elecys 2010. Anova / Dunnet’s t test was used when comparing
means. The diagnostic utility of BNP was compared with the
echocardiographic probability of LV dysfunction through the use
of receiver-operating characteristic (ROC) curves.
Results: Patients were divided into 2 groups on the basis of
whether they manifested normal or abnormal LV diastolic func-
tion by echocardiography. Patients diagnosed with abnormal
diastolic function had a mean BNP concentration of 285±31 pg/
mL, whereas the normal subjects had a mean BNP concentration
of 31±4 pg/mL. The difference between groups was significant (P
<0.001). The AUC for the ROC curve with BNP used to detect any
abnormal diastolic dysfunction was 0.91 (95% CI, P <0.001). A BNP
value of 62 pg/mL had a sensitivity of 85%, a specificity of 83% for
detecting diastolic dysfunction.
Conclusion: Our results suggest that the plasma BNP level is
influenced by diastolic dysfunction and an assay for BNP can
reliably detect the presence of diastolic dysfunction.
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Objective: The purpose of this study was to understand the usage
pattern of antihypertensive drugs and their fixed dose combina-
tion in clinical practice.
Methods: Doctors were asked to fill a questionnaire based on their
clinical experiences in dealing with patients with hypertension.
These questions were to be answered based on the doctor’s clin-
ical experience. Descriptive statistics were used to describe the
results.
Results: We collected completely filled questionnaires from 427
doctors. 46.33 % doctors in their clinical practice encounter 20- 40
newly diagnosed hypertensive patients per month. Among all the
patients with newly diagnosed hypertensive there were about 10-
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20% patients from a younger age group i.e. 25 e 35 years. Mean 39
% of patients with newly diagnosed hypertension are uncon-
trolled with monotherapy. Among the overall patients receiving
antihypertensive therapy mean 53 % of patients are prescribed an
ARB. About 75% & 61% of doctors prefer Olmesartan as the ARB of
choice in young & elderly patients with newly diagnosed hyper-
tension, respectively. 84.79 % of doctors are of the opinion that
Olmesartan would provide early control of blood pressure as
compared to other ARBs. Combination of ARB+Diuretic is most
commonly preferred by doctors for patients with stage 2 hyper-
tension whereas ARB+CCB for diabetic hypertensive patients. In
our study, ARBs had least rate of adverse event & discontinuation
among all anti-hypertensive groups of drugs.
Conclusion: This study recognizes the pattern of presentation of
hypertension in general population and the current trends in
utilization of antihypertensive therapy. Majority of hypertensive
patients are uncontrolled with monotherapy. Angiotensin recep-
tor blockers are the preferred class of drugs with least adverse
event rate and maximum compliance.
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Objective: A post marketing Prescription-Event Monitoring study
was undertaken to assess the safety of FDC of Olmesartan,
Amlodipine and Hydrochlorothiazide, in real world clinical set-
tings in India.
Methods: Physicians were sent PEM forms requesting clinical
event data on patients prescribed FDC of Olmesartan (20/40mg),
Amlodipine (5mg) and hydrochlorothiazide (12.5mg). Data on pa-
tient’s demographics, indication for FDC, concomitantmedication
and other relevant history was collected and analyzed.
Results:Datacollected from4763patientswasanalyzed.Meanageof
the populationwas 55 yearswith 59.25%males. Common indication
for the FDCwas uncontrolled hypertension (60.74%).Weaknesswas
themost common event reported (0.29%), followed by pedal odema,
dizziness persistent hypertension 0.27%, 0.23%, 0.23%, respectively.
Less common events reported were Headache (0.08%), gastritis
(0.06%), stroke (0.06%), chest pain (0.04%), LRTI (0.04%), myalgia
(0.04%). Diarrhea, Labyrinthitis, Itching, UTI, Hyponatremia, hypo-
tension and hypersomnia was seen in 0.02% patients. Events were
more common in patientswith uncontrolled hypertension (60.74%).
In other associated conditions diabetes and dyslipidemia was pre-
sent in 37.90% and 35.10% respectively, 15.33% showed both
together. Concomitant statins, hypoglycemic and antiplatelet
agents were prescribed 42.26%, 33.67%, 24.69% respectively.
Conclusions: The FDC of Olmesartan, Amlodipine and Hydro-
chlorothiazide was found to be safe and well tolerated when
prescribed in patients for the management of hypertension.
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Aims: The present study was designed to estimate the prevalence
of hypertension among primary school children in Delhi.
Methods: The study was conducted at National Heart Institute,
New Delhi and 10 primary schools of Delhi. All schools were co-
education schools. The ages of children were from 5 to 15 years. A
total of 2011 students were examined for blood pressure (BP) and
anthropometry. Appropriate size BP cuff was used. Pre-hyperten-
sion was defined as Systolic blood pressure (SBP) and/or Diastolic
blood pressure (DBP) between 90th and 95th percentile. Hyperten-
sion was defined as SBP and/or DBP over 95th percentile. Children
having hypertension in first and second recording; repeat mea-
surement was done to confirm hypertension after a week.
Results: The mean age of students was 10.78 ± 2.98 years, mean
height was 141.49 ± 16.38 cms, mean SBP was 103.34 ± 9.0 mm Hg
and mean DBP was 65.97 ± 6.64 mm Hg. Prevalence of obesity in
hypertensives was 8.7% against normotensive 1.1% (p<0.05).
Prevalence of hypertension in family members of hypertensive
was 18.6% and in normotensive 13.1% (p¼0.1). Prevalence of dia-
betes mellitus in family members of hypertensive was 23.4% and
13.7% in normotensive (p<0.05); while prevalence of ischemic
heart disease in family members was 12.34% in hypertensive and
8.3% in normotensive (p<0.05).The prevalence in boys was 3.3% (5-
9 years 2.3%, 10-12 years 4.6%, and 13-15 years 2.9%) and in girls
was 2.9% (5-9 years 2.5%, 10-12 years 2.8%, 13-15 years 3.4%). The
overall prevalence of high BP in school going children of 5-15 years
age was 3.1% (63/2011).
Conclusions: Prevalence of hypertension in school children was
3.1%. We observed obesity, family history of diabetes mellitus,
ischemic heart disease to be significant association for childhood
hypertension.
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Background: Calcium antagonists are now widely used for the
treatment of various types of hypertension. Hypertension is a
widespread public health problem and a major risk factor for
cardiovascular and cerebrovascular diseases. Despite their
ability to lower the high blood pressure effectively, calcium
antagonists do not always protect against cardiovascular com-
plications. Amlodipine used as antihypertensive for long period.
Cilnidipine has two actions, block L-type Ca channels in
vascular smooth muscle, which exerts an antihypertensive ef-
fect similar to L-type Ca channel blockers (e.g., amlodipine), and
block N-type Ca channels at sympathetic nerve endings, which
suppresses increased sympathetic activity in animal models
and human.
We compare the clinical effectiveness of Amlodipine and Cil-
nidipine on blood pressure, heart rate, and proteinuria
Method: The studywas prospective, randomized open lable study.
Total 50 patients were included in study of that 24 patient were on
cilnidipine 10-20 mg and amlodipine 5-10 mg. 12 patients of
amlodipine group and 16 patients of cilnidipine group were dia-
betic. 10 and 12 patients of amlodipine and cilindipine group had
proteinuria respectively. Both groupwere followed for 6months at
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